The future of the global colorectal cancer market looks promising with opportunities in the surgery and radiation therapy, chemotherapy, targeted therapies and resistance to pharmacological therapies markets.
- Within the diagnosis category, colonoscopy will remain the largest segment over the forecast period as the increasing demand for accurate colorectal screening.
- Within the treatment category, chemotherapy will remain the largest segment due to the growing prevalence of colorectal cancer cases.
- In terms of regions, North America will remain the largest region over the forecast period due to the increasing colorectal cancer cases driving screening demand.
Emerging Trends in Colorectal Cancer Market
The colorectal cancer market is evolving through advances in molecular diagnostics, noninvasive screening, and precision therapies during 2025 and 2026. Lucintel market coverage reflects increasing emphasis on earlier detection, biomarker guided treatment, and improved clinical outcomes, alongside persistent affordability and access concerns.- Noninvasive Screening Expansion: In June 2026, LabCorp introduced nationwide access to Colo Sense, an RNA based screening test; in July 2026, the FDA approved Free Nome’s Simple Screen CRC blood test. These developments expand screening choices and may improve participation over the next three to five years.
- Molecular Diagnostic Innovation: In 2026, the American Cancer Society updated screening guidance to include newer stool RNA and next generation stool DNA testing options. These technologies improve the range of noninvasive detection methods, supporting wider screening adoption and demand for laboratory testing.
- Biomarker Driven Therapies: In January 2025, the FDA approved sotorasib with panitumumab for KRAS G12C mutated metastatic disease; in February 2026, it granted traditional approval to encorafenib combination therapy for BRAF V600E mutated disease. These advances strengthen demand for mutation testing and personalized treatment.
- Immunotherapy and Organ Preservation: In October 2026, the FDA approved atezolizumab with chemotherapy for stage III mismatch repair deficient colon cancer and dostarlimab for eligible locally advanced rectal cancer. These approvals broaden treatment options and may reduce reliance on invasive procedures for selected patients.
- Data Driven Early Detection: In June 2026, researchers reported a machine learning model evaluated using 87,825 screening colonoscopies and validated against 21,957 others. Such risk stratification could help providers prioritize high risk patients and improve screening efficiency over the next three to five years.
Recent Developments in the Colorectal Cancer Market
The colorectal cancer market has seen significant advances in screening technologies, biomarker guided medicines, and immunotherapy between 2024 and 2026. Lucintel’s market coverage reflects how regulatory approvals and clinical research are expanding treatment options while increasing demand for precision diagnostics and individualized care.- Blood Based Screening Approval: In July 2024, the FDA approved Guardant Health’s Shield blood test for primary colorectal cancer screening in average risk adults aged 45 and older. This milestone broadened noninvasive screening options and may encourage wider participation, expanding diagnostic market demand over the next three to five years.
- Targeted Therapy Expansion: In June 2024, the FDA granted accelerated approval to adagrasib with cetuximab for previously treated KRAS G12C mutated colorectal cancer. The decision expanded treatment options for a genetically defined patient group and should strengthen demand for mutation testing and targeted medicines.
- First Line Precision Treatment: In December 2024, the FDA granted accelerated approval to encorafenib with cetuximab and mFOLFOX6 for BRAF V600E mutated metastatic colorectal cancer. The combination brought targeted treatment into earlier disease management and is expected to increase biomarker testing and personalized therapy adoption.
- KRAS Targeted Combination Approval: In January 2025, the FDA approved sotorasib with panitumumab for previously treated KRAS G12C mutated metastatic colorectal cancer. Approval of an accompanying QIAGEN companion diagnostic reinforced the link between molecular testing and treatment selection, supporting growth in precision oncology.
- Immunotherapy Advancement: In April 2025, the FDA approved nivolumab with ipilimumab for unresectable or metastatic MSI H or dMMR colorectal cancer in patients aged 12 and older. The approval expanded immunotherapy use and may shift treatment decisions toward biomarker guided care over the next three to five years.
Strategic Growth Opportunities in the Colorectal Cancer Market
The colorectal cancer market presents growth opportunities through noninvasive screening, precision diagnostics, targeted medicines, and earlier intervention. Recent regulatory approvals between 2024 and 2025 have expanded screening and treatment options. Lucintel’s market coverage highlights commercial potential in diagnostic innovation and personalized oncology as healthcare systems seek improved outcomes and more efficient care delivery.- Expand Blood Based Screening: Guardant Health received Medicare Advanced Diagnostic Laboratory Test status for Shield in March 2025, establishing reimbursement of USD 1,495 for its initial nine month payment period. Wider payer coverage creates opportunities for diagnostic providers to reach underserved screening populations.
- Develop Next Generation Diagnostics: In July 2026, the FDA approved Freenome’s SimpleScreen CRC blood test for average risk adults aged 45 and older. Abbott’s exclusive US commercialization agreement creates distribution potential for accessible screening and laboratory services.
- Commercialize Targeted Therapies: In February 2026, the FDA granted traditional approval to Pfizer’s encorafenib combination for BRAF V600E mutated metastatic disease, supported by phase three results involving 479 patients in the primary comparison. This creates opportunities for targeted drug development and companion diagnostics.
- Expand Immunotherapy Applications: In April 2025, the FDA approved nivolumab plus ipilimumab for patients aged 12 and older with unresectable or metastatic MSI H or dMMR colorectal cancer. Further biomarker driven treatment development offers revenue potential in specialized oncology care.
- Strengthen Precision Diagnostics: In January 2025, the FDA approved sotorasib with panitumumab for previously treated KRAS G12C mutated metastatic colorectal cancer. Wider adoption of mutation specific therapies creates opportunities for validated testing, laboratory partnerships, and integrated treatment services.
Colorectal Cancer Market Drivers and Challenges
The colorectal cancer market is influenced by rising disease incidence, expanding screening programs, advances in precision medicine, and increasing demand for effective therapies. Lucintel’s market perspective highlights how technological innovation, healthcare spending, regulatory decisions, and access to diagnosis shape treatment adoption, while affordability and unequal healthcare infrastructure continue to constrain progress.The factors responsible for driving the colorectal cancer market include:
- Precision Medicine: In February 2026, the FDA granted traditional approval to encorafenib combination therapy for BRAF V600E mutated metastatic disease. Biomarker guided treatment should support personalized therapy adoption over the next three to five years.
- Immunotherapy Innovation: In May 2025, the National Cancer Institute reported expanded immunotherapy options for advanced MSI H or dMMR colorectal cancer. Continued clinical advances should increase demand for targeted immune based treatments.
- Screening Expansion: In 2026, the American Cancer Society reaffirmed screening from age 45 for average risk adults. Wider screening should increase early diagnosis and intervention over the coming years.
- Rising Disease Burden: In February 2026, the World Health Organization reported approximately 1.9 million new cases worldwide in 2022. This substantial disease burden will sustain demand for diagnostic and therapeutic services.
- Diagnostic Advances: In 2025, molecular testing and biomarker identification remained central to selecting appropriate therapies. The FDA’s treatment approvals require specific mutation identification, reinforcing the importance of validated diagnostic tests. Better testing should improve treatment selection and support precision oncology adoption.
The challenges facing the colorectal cancer market include:
- High Treatment Costs: Advanced biologics, immunotherapies, and molecular diagnostics can create substantial financial burdens. Limited reimbursement may restrict access, particularly in lower income healthcare systems, slowing equitable adoption over the next three to five years.
- Late Diagnosis: The WHO reported that colorectal cancer caused more than 900,000 deaths worldwide in 2022. Limited screening participation and delayed diagnosis can reduce treatment effectiveness and increase healthcare costs.
- Treatment Resistance: Tumor heterogeneity and acquired resistance can limit sustained responses to existing therapies. The need for repeated treatment changes and monitoring increases clinical complexity, encouraging continued research into more durable treatment strategies.
List of Colorectal Cancer Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies colorectal cancer market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the colorectal cancer market companies profiled in this report include:
- Abbott Diagnostics
- Alere
- Beckman Coulter
- Clinical Genomics
- Companion Dx
- Hoffmann La Roche
- Debiopharm
- Vaccinogen BD
Colorectal Cancer Market by Segment
The study includes a forecast for the global colorectal cancer market by diagnosis, treatment, and region.Diagnosis [Value ($B) from 2019 to 2035]:
- Digital Rectal Examination
- Fecal Occult Blood Test
- Flexible Sigmoidoscopy
- Colonoscopy
- Virtual Colonoscopy
Treatment [Value ($B) from 2019 to 2035]:
- Surgery and Radiation Therapy
- Chemotherapy
- Targeted Therapies
- Resistance to Pharmacological Therapies
- Others
Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Colorectal Cancer Market
The colorectal cancer market developments are shaped by advances in precision oncology, screening, and targeted treatment, alongside government efforts to improve early diagnosis. Lucintel’s market coverage reflects the importance of diagnostic innovation and therapeutic progress as healthcare systems address colorectal cancer through prevention, detection, and treatment.- United States: In April 2025, the Food and Drug Administration approved Bristol Myers Squibb’s nivolumab with ipilimumab for patients aged 12 years and older with unresectable or metastatic microsatellite instability high or mismatch repair deficient colorectal cancer. In July 2026, Freenome and Abbott announced FDA approval of SimpleScreen CRC, a blood based screening test for adults aged 45 and older at average risk. These developments expand immunotherapy options and screening access.
- China: In October 2025, Hansoh Pharma signed an agreement with Roche valued at up to USD 1.45 billion to develop and commercialize an investigational treatment targeting colorectal cancer and other solid tumors. Hansoh retained marketing rights in mainland China and several neighboring markets. The agreement strengthens international pharmaceutical collaboration and supports domestic drug development.
- Germany: In April 2025, Germany introduced equal colorectal cancer screening options for women and men aged 50 and older, including colonoscopy twice at a ten year interval or stool testing every two years. The Federal Joint Committee’s updated screening framework simplifies access and supports earlier detection, potentially increasing demand for diagnostic procedures.
- India: In July 2026, India’s Central Drugs Standard Control Organisation listed ipilimumab approval information covering combination treatment with nivolumab for unresectable or metastatic colorectal cancer with specific biomarkers. This regulatory development supports access to immunotherapy and broadens treatment options for eligible patients.
- Japan: In August 2025, Ono Pharmaceutical and Bristol Myers Squibb received supplemental approval for nivolumab plus ipilimumab for unresectable advanced or recurrent microsatellite instability high colorectal cancer. The approval expands immunotherapy use and strengthens treatment options for patients with biomarker defined disease.
Features of the Global Colorectal Cancer Market
- Market Size Estimates: Colorectal cancer market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: Colorectal cancer market size by various segments, such as by diagnosis, treatment and region in terms of value ($B).
- Regional Analysis: Colorectal cancer market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different diagnosis, treatment and regions for the colorectal cancer market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the colorectal cancer market.- Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the colorectal cancer market by diagnosis (digital rectal examination, fecal occult blood test, flexible sigmoidoscopy, colonoscopy, and virtual colonoscopy), treatment (surgery and radiation therapy, chemotherapy, targeted therapies, resistance to pharmacological therapies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years, and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Abbott Diagnostics
- Alere
- Beckman Coulter
- Clinical Genomics
- Companion Dx
- Hoffmann La Roche
- Debiopharm
- Vaccinogen BD
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

